Company news
Akari Therapeutics PLC news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
November 12, 2026
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
November 11, 2026
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
October 30, 2026
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
October 15, 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
April 6, 2026
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
December 23, 2025
Decks
The 5 newest of 32 decks. Every deck is listed under its year.
- Investor Presentation (November 2026)
Investor deck · 29 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 30 slides · October 2026
- Investor Presentation (September 2026)
Investor deck · 30 slides · September 2026
- Investor Presentation (August 2026)
Investor deck · 30 slides · August 2026
- Investor Presentation (June 2026)
Investor deck · 27 slides · June 2026